94 related articles for article (PubMed ID: 29617697)
1. Proteomic Profiling of Diffuse Large B-Cell Lymphomas.
Kwiecińska A; Porwit A; Souchelnytskyi N; Kaufeldt A; Larsson C; Bajalica-Lagercrantz S; Souchelnytskyi S
Pathobiology; 2018; 85(4):211-219. PubMed ID: 29617697
[TBL] [Abstract][Full Text] [Related]
2. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Uhl B; Prochazka KT; Pansy K; Wenzl K; Strobl J; Baumgartner C; Szmyra MM; Waha JE; Wolf A; Tomazic PV; Steinbauer E; Steinwender M; Friedl S; Weniger M; Küppers R; Pichler M; Greinix HT; Stary G; Ramsay AG; Apollonio B; Feichtinger J; Beham-Schmid C; Neumeister P; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887224
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
4. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
[TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
[TBL] [Abstract][Full Text] [Related]
6. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.
Baecklund E; Backlin C; Iliadou A; Granath F; Ekbom A; Amini RM; Feltelius N; Enblad G; Sundström C; Klareskog L; Askling J; Rosenquist R
Arthritis Rheum; 2006 Dec; 54(12):3774-81. PubMed ID: 17133544
[TBL] [Abstract][Full Text] [Related]
9. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
Gormley RP; Madan R; Dulau AE; Xu D; Tamas EF; Bhattacharyya PK; LeValley A; Xue X; Kumar P; Sparano J; Ramesh KH; Pulijaal V; Cannizzaro L; Walsh D; Ioachim HL; Ratech H
Am J Clin Pathol; 2005 Nov; 124(5):790-8. PubMed ID: 16203284
[TBL] [Abstract][Full Text] [Related]
10. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
11. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies.
Fassina A; Marino F; Siri M; Zambello R; Ventura L; Fassan M; Simonato F; Cappellesso R
Lab Invest; 2012 Nov; 92(11):1574-82. PubMed ID: 22964854
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
13. [Gene expression profiling of diffuse large B-cell lymphoma in China].
Liu YH; Li L; Liu G; Zhuang HG; Luo DL; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):79-83. PubMed ID: 17493379
[TBL] [Abstract][Full Text] [Related]
14. Expression of transmembrane adaptor protein PAG/Cbp in diffuse large B-cell lymphoma: immunohistochemical study of 73 cases.
Svec A
Pathol Res Pract; 2007; 203(4):193-8. PubMed ID: 17382485
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
16. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
[TBL] [Abstract][Full Text] [Related]
17. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
20. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
